e-learning
resources
Vienna 2012
Monday, 03.09.2012
Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ProSP-B as a possible biomarker in idiopathic interstitial pneumonias (ILD)
M. Kreuter, A.K. Rossler, N. Kahn, K. Hornemann, T. Muley, F. Herth (Heidelberg, Germany)
Source:
Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Session:
Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Session type:
Poster Discussion
Number:
1767
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kreuter, A.K. Rossler, N. Kahn, K. Hornemann, T. Muley, F. Herth (Heidelberg, Germany). ProSP-B as a possible biomarker in idiopathic interstitial pneumonias (ILD). Eur Respir J 2012; 40: Suppl. 56, 1767
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Non-IPF idiopathic interstitial pneumonia (IIPs)
Source: ERS Course 2016
Year: 2016
Clinical-radiographic-pathologic diagnosis in idiopathic interstitial pneumonia (IIP)
Source: Eur Respir J 2002; 20: Suppl. 38, 61s
Year: 2002
Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018
Histology and pathogenesis of usual interstitial pneumonia (UIP)
versus
nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Clinical categorisation of idiopathic interstitial pneumonia
Source: Annual Congress 2005 - Idiopathic pulmonary fibrosis: new concepts in its pathogenesis and management
Year: 2005
CT features of fibrosing alveolitis in rheumatoid arthritis (FARA): a comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP)
Source: Eur Respir J 2003; 22: Suppl. 45, 197s
Year: 2003
Fibrosing alveolitis in rheumatoid arthritis (FARA):a survival comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP)
Source: Eur Respir J 2003; 22: Suppl. 45, 197s
Year: 2003
Histopathological assessment and classification
Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias
Year: 2006
Clinical significance of histological classification of idiopathic interstitial pneumonia
Source: Eur Respir J 2002; 19: 275-283
Year: 2002
The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias
Source: Eur Respir Rev 2008; 17: 108-115
Year: 2008
Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Source: Eur Respir J 2002; 19: 1114-1118
Year: 2002
Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005
Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia
Source: International Congress 2017 – Lung function testing
Year: 2017
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Source: Eur Respir J 2011; 37: 1119-1127
Year: 2011
Non-IPF idiopathic interstitial pneumonias
Source: School Course 2014 - Interstitial lung diseases
Year: 2014
Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies
Source: Eur Respir J 2002; 20: Suppl. 38, 586s
Year: 2002
Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis
Source: Eur Respir J 2001; 18: 43S-55S
Year: 2001
Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept